Fig. 1: Discovery of SWII-binding KRAS G12C dual inhibitors.
From: Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
a Chemical structures of analogs prepared. b RAS/RAF disruption potency of analogs. c GDP exchange inhibition potency of analogs. For Figs. 1b and 1c, IC50s for 2, 3, 4, and 5 represent the average of two independent experiments; IC50s for 1, 6, 7, 8, and divarasib represent the average of three independent experiments. Where applicable, data are given as mean ± SD. Source data are provided as a Source Data file.
